Arbitel AM 5+40 mg Tablet (Amlodipine + Telmisartan) – ACI Limited

1. About Arbitel AM 5+40 mg (Amlodipine + Telmisartan)

Arbitel AM 5+40 mg is a fixed-dose combination (FDC) of Amlodipine 5 mg (dihydropyridine calcium channel blocker) and Telmisartan 40 mg (angiotensin II receptor blocker / ARB), manufactured by ACI Limited, Bangladesh. This dual-mechanism antihypertensive combines two complementary drug classes — CCB for direct vasodilation and ARB for RAAS blockade — producing additive blood pressure reduction with a favourable tolerability profile.

The ARB + CCB combination is endorsed by major hypertension guidelines (JNC, ESC/ESH, ISH) as a preferred first-line combination for hypertension requiring dual therapy, particularly in patients with T2DM, CKD, or high cardiovascular risk. The fixed-dose formulation improves adherence by reducing pill burden from two tablets to one. Arbitel AM 5+40 mg is the starting combination dose — suitable for patients new to dual therapy or those transitioning from lower doses of either component.

2. Mechanism of Action

Telmisartan 40 mg (ARB): Selectively blocks AT1 receptors → prevents angiotensin II-mediated vasoconstriction, aldosterone release, and sympathetic activation → reduces peripheral resistance and blood volume → lowers blood pressure. Additional renal protection via reduced glomerular efferent pressure. PPAR-γ partial agonism improves insulin sensitivity.

Amlodipine 5 mg (Dihydropyridine CCB): Blocks L-type voltage-gated calcium channels in vascular smooth muscle and cardiac tissue → inhibits calcium-dependent muscle contraction → arteriolar vasodilation → reduced peripheral resistance → lowered blood pressure. Long t½ (~35–50h) provides smooth once-daily coverage. Does not cause significant negative inotropy at standard doses.

Complementary mechanisms: Amlodipine’s arteriolar vasodilation can trigger mild reflex tachycardia and sodium retention (via renin activation), which ARBs directly counteract — producing additive BP reduction while minimising amlodipine’s side effect of ankle oedema (ARBs reduce venous pressure and sodium retention responsible for peripheral oedema).

3. Indications

• Essential Hypertension requiring dual-class combination therapy
• Hypertension + T2DM: ARB renoprotection + CCB BP control — preferred combination
• Hypertension + CKD/Microalbuminuria: RAAS blockade + effective BP reduction
• Patients transitioning from separate amlodipine 5 mg + telmisartan 40 mg tablets to simplified FDC
• Hypertension + Stable Angina: Amlodipine is antianginal; telmisartan adds CV risk reduction

4. Dosage and Administration

Standard: One tablet once daily. Arbitel AM 5+40 mg provides amlodipine 5 mg + telmisartan 40 mg per day.

Step-up: If BP not at target on Arbitel AM 5+40 mg, upgrade to Arbitel AM 5+80 mg (higher telmisartan dose). Alternatively, add a thiazide diuretic.

Take at the same time each day, with or without food. Do not crush or chew film-coated tablet.

5. Contraindications

• Hypersensitivity to amlodipine, telmisartan, or dihydropyridines
• Pregnancy (telmisartan teratogenic/fetotoxic — all trimesters)
• Severe hepatic impairment (both components metabolised/eliminated hepatically)
• Cardiogenic shock, haemodynamically significant aortic stenosis
• Concurrent aliskiren in patients with diabetes or eGFR <60 ml/min

6. Warnings and Precautions

Pregnancy: Strictly contraindicated. Stop immediately if pregnancy confirmed; switch to safe antihypertensive.

Hypotension: Additive BP-lowering. Volume-depleted patients at risk. Start at lower telmisartan dose (Arbitel 20–40 mg) alone before combining, or initiate combination cautiously with monitoring.

Amlodipine oedema: Peripheral oedema (ankle swelling) from amlodipine occurs in ~5–10% of patients but is less common with combined ARB than with CCB alone. Oedema that is positional (worse in evening, better on waking) is pharmacological, not a sign of heart failure.

Renal/K+: Monitor as for telmisartan alone. RAAS blockade may raise potassium and creatinine in CKD.

Liver disease: Amlodipine highly protein-bound and hepatically metabolised; telmisartan is biliarily eliminated. Use with caution in hepatic impairment. Max telmisartan 40 mg in moderate hepatic impairment — Arbitel AM 5+40 mg is appropriate.

7. Side Effects

From Amlodipine: Peripheral oedema/ankle swelling (dose-dependent; reduced by ARB), headache, flushing, palpitations, dizziness.

From Telmisartan: Dizziness, fatigue, back pain, URTI, diarrhoea, hyperkalaemia.

Combination: Lower incidence of amlodipine oedema vs amlodipine alone. No cough from telmisartan component.

Rare: Gingival hyperplasia (amlodipine), hepatic dysfunction, angioedema.

8. Drug Interactions

• Other antihypertensives/diuretics: Additive BP lowering
• CYP3A4 inhibitors (clarithromycin, itraconazole, grapefruit): Increase amlodipine levels — monitor BP
• CYP3A4 inducers (rifampicin, carbamazepine): Reduce amlodipine efficacy
• NSAIDs: Reduce telmisartan efficacy; increase renal impairment risk
• Digoxin: Telmisartan raises digoxin Cmax — monitor levels
• K+-sparing agents: Hyperkalaemia risk from telmisartan component

9. Evidence: ARB + CCB Combination

The ACCOMPLISH trial (11,506 patients) compared ACE inhibitor + CCB (benazepril + amlodipine) vs ACE inhibitor + thiazide in high-risk hypertensives — the CCB combination was superior, reducing cardiovascular events by 20%. ARB + CCB combinations have similar evidence of superiority over ARB + thiazide for patients with T2DM, CKD, or high CV risk. Meta-analyses show ARB + CCB combinations reduce proteinuria more effectively than either agent alone in diabetic nephropathy — making Arbitel AM a particularly rational combination for diabetic hypertension.

10. ARB + CCB in Diabetic Hypertension

For diabetic hypertensive patients in Bangladesh, the ARB + CCB combination offers: (1) Renoprotective RAAS blockade from telmisartan; (2) Effective BP reduction from amlodipine; (3) Metabolic neutrality — CCBs and ARBs do not worsen glucose or lipids; (4) Reduced ankle oedema compared to CCB monotherapy; (5) No cough. Most international diabetes guidelines (ADA, IDF, BADAS) recommend ARB + CCB or ARB + thiazide as preferred second-line combinations for diabetic hypertension when monotherapy is insufficient.

11. Arbitel AM 5+40 vs 5+80 mg: Which to Choose?

Both formulations contain amlodipine 5 mg — the difference is telmisartan dose. Arbitel AM 5+40 mg is for: patients initiating dual ARB+CCB therapy, those previously on telmisartan 40 mg monotherapy who need amlodipine added, or those requiring moderate BP control without maximum RAAS blockade. Arbitel AM 5+80 mg is for: patients requiring maximum telmisartan dose (cardiovascular risk reduction, maximum renoprotection in diabetic nephropathy, significant hypertension). If BP remains above target on Arbitel AM 5+40 mg after 4–8 weeks, step up to Arbitel AM 5+80 mg.

12. ACI Limited Arbitel AM Range

ACI Limited’s Arbitel AM range: Arbitel AM 5+40 mg (standard starting combination) and Arbitel AM 5+80 mg (maximum telmisartan combination). Both provide the proven ARB + CCB combination in a single once-daily tablet, minimising pill burden and maximising adherence for Bangladesh’s hypertensive patients.

13. Storage

• Below 30°C, cool, dry, protected from moisture
• Original blister pack. Keep from children.
• Do not use after expiry.

Frequently Asked Questions (FAQ)

Q1: What is Arbitel AM 5+40 mg used for?

Arbitel AM 5+40 mg is a combination antihypertensive containing Amlodipine 5 mg (calcium channel blocker) and Telmisartan 40 mg (ARB). It is used when a single antihypertensive is insufficient to control blood pressure, or when patients are already on both drugs separately and want a simplified single-tablet regimen. Particularly suited for T2DM patients with hypertension — telmisartan provides renal protection and telmisartan+amlodipine together lower BP more than either alone, with complementary mechanisms.

Q2: Will Arbitel AM cause ankle swelling?

Ankle swelling (peripheral oedema) is the most common side effect of amlodipine monotherapy (affecting 5–10% of patients). However, in the Arbitel AM combination, telmisartan’s ARB effect reduces the sodium retention and venous pressure that contribute to amlodipine-induced oedema. Clinical trials show significantly lower rates of ankle oedema with ARB + amlodipine combinations vs amlodipine alone. If you already experienced ankle swelling on amlodipine monotherapy, switching to Arbitel AM may help reduce it while maintaining BP control.

Q3: Is Arbitel AM (Amlodipine + Telmisartan) safe for diabetic patients?

Yes — Arbitel AM is one of the preferred combinations for diabetic hypertension. Both amlodipine and telmisartan are metabolically neutral — they do not impair glucose control, worsen insulin resistance, or raise lipids. Telmisartan’s ARB effect provides additional kidney protection, reducing proteinuria and slowing diabetic nephropathy progression. The ARB + CCB combination is specifically recommended by diabetes guidelines (ADA, IDF) when monotherapy fails to achieve blood pressure targets in T2DM patients.

Q4: Can I take Arbitel AM if I had cough on another BP tablet?

Yes — if you developed dry cough on an ACE inhibitor (enalapril, ramipril, lisinopril), Arbitel AM is an excellent alternative. The telmisartan (ARB) component of Arbitel AM does NOT cause dry cough — ARBs work by a different mechanism that does not increase bradykinin levels (the cause of ACE-inhibitor cough). In South Asian/Bangladeshi patients, ACE-inhibitor-induced cough affects 20–30% of patients due to genetic differences in bradykinin metabolism. Arbitel AM provides equivalent or better blood pressure control without this troublesome side effect.